Connect with us

Tech

Bit Bio’s “enter button for the keyboard to the software of life” nabs the company $41.5 million

Published

on

DNAnexus raises $100M for a cloud-based analytics platform aimed at genomics and other clinical big data

Bit Bio, the brand new startup which pitches itself because the “enter button for the keyboard to the software program of life” solely wanted three weeks to boost its newest $41.5 million spherical of funding.

Originally referred to as Elpis Biotechnology and named for the Greek goddess of hope, the Cambridge, England-based firm was based by Mark Kotter in 2016 to commercialize know-how that may cut back the price and enhance the manufacturing capability for human cell traces. These cells can be utilized in focused gene therapies and as a technique to speed up drug discovery at pharmaceutical corporations.

The firm’s objective is to have the ability to reproduce each human cell kind.

“We’re simply at a really essential time in biology and medication and the bottleneck that has grow to be actually clear is a scalable supply of strong human cells,” mentioned Kotter. “For drug discovery that is vital. When you have a look at failure charges in medical trials they’re at an all time excessive… that’s in direct contradiction to the huge developments in biotechnology in analysis and the sphere.”

In the seventeen years since scientists utterly mapped the human genome, and eight years since scientists started utilizing the gene enhancing know-how referred to as CRISPR to edit genetic materials, there’s been an explosion of remedies primarily based on particular person affected person’s genetic materials and new medication developed to extra exactly goal the mechanisms that pathogens use to unfold by means of organisms.

These remedies and the small molecule medication being created to cease the unfold of pathogens or cut back the consequences of illness require vital testing earlier than coming to market — and Bit Bio’s founder thinks his firm can each cut back the time to market and provide new remedies for sufferers.

Read More:  Bellman raises $4.5 million for its property management platform

It’s a thesis that had traders just like the well-known serial biotech entrepreneur, Richard Klausner, who served as the previous director of the National Cancer Institute and founding father of revolutionary biotech corporations like Lyell Immunopharma, Juno, and Grail, leaping on the probability to spend money on Bit Bio’s enterprise, based on Kotter.

Joining Klausner are the well-known biotech funding companies Foresite Capital, Blueyard Capital and Arch Venture Partners.

“Bit Bio relies on stunning science. The firm’s know-how has the potential to carry the long-awaited precision and reliability of engineering to the applying of stem cells,” mentioned Klausner in an announcement. “Bit Bio’s strategy represents a paradigm shift in biology that may allow a brand new era of cell therapies, bettering the lives of hundreds of thousands.”

Photo: Andrew Brookes/Getty Images

Kotter’s personal path to develop the know-how which lies on the coronary heart of Bit Bio’s enterprise started a decade in the past in a laboratory in Cambridge University. It was there that he started analysis constructing on the revolutionary discoveries of Shinya Yamanaka, which enabled scientists to rework human grownup cells into embryonic stem cells.

“What we did is what Yamanaka did. We turned the whole lot the other way up. We wish to understand how every cell is outlined… and as soon as we all know that we will flip the swap,” mentioned Kotter. “We discover out which transcription components code for a single cell and we flip it on.”

Kotter mentioned the know-how is like importing a brand new program into the embryonic stem cell.

Read More:  Volcker Rule reforms expand options for raising VC funds

Although the corporate remains to be in its early days, it has managed to draw just a few key prospects and launch a sister firm primarily based on the know-how. That firm, Meatable, is utilizing the identical course of to make lab-grown pork.

Dutch startup Meatable is creating lab-grown pork and has $10 million in new financing to do it

Meatable is the earliest claimant to a commercially viable, patented course of for manufacturing meat cells with out the necessity to kill an animal as a prerequisite for cell differentiation and progress.

Other corporations have relied on fetal bovine serum or Chinese hamster ovaries to stimulate cell division and manufacturing, however Meatable says it has developed a course of the place it may pattern tissue from an animal, revert that tissue to a pluripotent stem cell, then tradition that cell pattern into muscle and fats to supply the pork merchandise that palates around the globe crave.

“We know which DNA sequence is liable for shifting an early-stage cell to a muscle cell,” says Meatable chief government Krijn De Nood.

If that sounds much like Bit Bio, that’s as a result of it’s the identical tech — simply used to make animal as an alternative of human cells.

Bit Bio’s “enter button for the keyboard to the software

Image: PASIEKA/SCIENCE PHOTO LIBRARY/Getty Images

If Meatable is one approach to commercialize the cell differentiation know-how, Bit Bio’s partnership with the drug improvement firm Charles River Laboratories is one other.

“We really do have a income producing enterprise aspect utilizing human cells for analysis and drug discovery. We have a partnership with Charles River Laboratories the massive preclinical contract analysis group,” Kotter mentioned. “That partnership is the place we have now given early entry to our know-how to Charles River… They have their very own ordinary enterprise purchasers who need them to assist with their drug discovery. The huge bottleneck in the meanwhile is entry to human cells.”

Read More:  Tesla delivered 90,650 vehicles in second quarter, a 4.9% decline

Drug trials fail as a result of the remedies developed both are poisonous or don’t work in people. The distinction is that almost all experiments to show how efficient the remedies are depend on animal testing earlier than making the leap to human trials, Kotter mentioned.

The firm can also be getting ready to develop its personal cell therapies, based on Kotter. There, the largest promoting level is the elevated precision that  Bit Bio can carry to precision medication, mentioned Kotter. “If you have a look at these cell therapies in the meanwhile you get combined luggage of cells. There are some that work and a few which have harmful unwanted effects. We assume we will be exact [and] security is the largest factor at this level.”

The firm claims that it may produce cell traces in lower than per week with 100 p.c purity, versus the combined luggage from different corporations cell cultures.

“Our moonshot objective is to develop a platform able to producing each human cell kind. This is feasible as soon as we perceive the genes governing human cell behaviour, which finally kind the ‘working system of life’,” Kotter mentioned in an announcement. “This will unlock a brand new era of cell and tissue therapies for tackling most cancers, neurodegenerative problems and autoimmune ailments and speed up the event of efficient medication for a spread of situations. The help of main deep tech and biotech traders will catalyse this distinctive convergence of biology and engineering.”

 

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending